Company inventory work in the first quarter
Release time:
2020-08-14
Company Counts First Quarter Work
Proposes Second Quarter Work Requirements
News 4# October 23 , 24 , The Company successively held work analysis meetings for cement sector, pharmaceutical industry and directly affiliated enterprises to summarize the gains and losses of the first quarter work and put forward requirements for the next stage, especially the second quarter work. At the
analysis meeting, the person in charge of each enterprise reported the work situation in the first quarter in the form of PPT , focusing on analyzing the existing problems and proposing solutions and improvement plans. Chairman Jiang Xiaomeng, general manager Yu Jianhong and other group company leaders commented on the work of each business sector one by one based on the economic and technical data of each enterprise in the first quarter, pointed out the highlights of the work, analyzed the problems and deficiencies, and put forward guidance and work requirements.
Cement Plate: Improve Operational Efficiency and Establish Competitive Advantage
In the first quarter, the overall efficiency of the two cement enterprises increased year-on-year, the overall production indicators improved, and the optimization of management institutions and positions was steadily advancing. Company leaders pointed out that the overall improvement of the national cement industry in 2018 has brought about an improvement in benefits, but because of this, the management and technical advantages of peak cement enterprises have not been fully reflected. With the progress of technology in the cement industry, enterprises continue to increase the intensity of technological transformation, the original advantages continue to reduce, and the gap with the advantages of enterprises is also widening. Therefore, the peak cement must clear ideas, strengthen management innovation and technological innovation, and strive to improve the efficiency of enterprise operation. The
meeting required the two cement enterprises to make equipment management the top priority of their work. The leaders in charge, departments and team leaders should "sink" to the production line, so as to drive the inspection workers and maintenance workers to find and solve problems in time, effectively improve the quality of inspection and equipment maintenance, and ensure the "zero defect" operation of equipment. Further strengthen the management of raw materials, to ensure the stability and reliability of the quality of raw materials, all incoming indicators must be kept in a controllable state, so as to provide guarantee for the stability of product quality; further deepen lean management, strive for excellence in every work detail, and strive to achieve every detail Optimum, so as to improve the overall operation level of the enterprise; with the country and the whole society paying attention to environmental protection, as a traditional manufacturing enterprise, it is necessary to continuously promote the creation of "green factories" and "standardized demonstration factories", and earnestly do a good job in environmental protection and safety management.
According to the specific conditions of the two enterprises, the meeting also requested Daye Peak to further speed up the handling of hazardous waste disposal and related procedures for mining in Xiyeshan Mine, and to do a solid job in environmental improvement and market control. Yunnan Jianfeng should pay close attention to mine renovation, scientific use of lignite and clay mine related work, and strengthen market management to ensure the balance and stability of production and sales.
Peak Pharmaceutical: Grasp the situation, strengthen innovation, and seek a breakthrough
In the recent period, pharmaceutical companies have made significant progress in factory management, technical research, organization optimization, and sales team construction. However, with a series of changes such as the reform of the medical system and the rectification of the pharmaceutical market, the pressure on the production and operation of enterprises has also increased. How to break through the development bottleneck is the most important problem that pharmaceutical companies urgently need to solve. The meeting requested that pharmaceutical companies should fully grasp the current situation, clarify where their current profit growth points are, where future growth points are, how to solve pain points and difficulties, and strive to achieve "curve overtaking" and seek greater development space. Meeting
requires pharmaceutical companies to fully understand the development trend of the industry brought about by the reform of the medical system, strengthen the innovation of marketing mode, management mode and incentive mechanism, increase the introduction of marketing talents, and realize the breakthrough of marketing; new product research and development and consistency evaluation should be carried out in stages on a weekly and monthly basis, set goals, continuously promote and summarize, and ensure the orderly development of the work; the selection and grafting of new development projects and new varieties should have a clear direction, and establish corresponding professional teams and responsibility assessment objectives; the management of new projects should have clear objectives and plans, strengthen management communication and coordination with cooperative enterprises, fully and effectively integrate existing resources, establish competitive advantages, and truly take the road of differentiated development.
Peak Health: Strengthen Scientific and Technological Innovation, Strengthen Quality Management, Accelerate Marketing Breakthrough
Aiming at several major product lines of Peak Health, the meeting called for strengthening the procurement management, quality management and production standards of health care products raw materials, strictly controlling the quality of products, speeding up the construction of health care products marketing team, formulating standardized promotion mode, speeding up marketing expansion and achieving breakthroughs; Clarify the positioning of plant products, focus on the promotion, through technological innovation, patents, the formulation of industry standards and other methods, improve the market threshold, so as to establish a leading advantage in the extract industry; traditional Chinese medicine pieces should strengthen the construction of raw material base, and small package pieces, granules and other attempts; all kinds of products should do a good job in the coordination of production and sales, and strictly control the production cost.
International Trade Company: Strengthen management, improve service quality, and expand enterprise scale
The meeting requires international trade companies to combine the actual situation of the enterprise, strengthen on-site management, eliminate management loopholes, and reduce operating costs; improve management standardization Level, improve service quality; carry out various tasks in a targeted manner, form a business model with advantages and own characteristics, and expand the business scale as soon as possible, establish industry competitive advantage.
Cable Company: Build Confidence, Prevent Risks, Build Brand
In view of the current cable market situation, the meeting asked the cadres and employees of Jianfeng Cable Company to cheer up, build confidence, pay close attention to market changes, pay attention to prevent the intellectual property risks of OEM products and the sales risks brought by raw material price fluctuations, and strengthen cost control. At the same time, strengthen technical research and strive to build independent brands and markets, increase profitability and strive for greater benefits. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31